Replies to post #323791 on ORIONS Money Stocks

[oldberkeley]

ACST I'm expecting trial results in the last week of this month.

What I especially like about this trigliceride trial is this from the company:

Upon reaching the number of targeted patients, a planned second blinded interim analysis indicated a significant clinical signal, without any safety concerns. Given that the stopping threshold had been met, the data review committee recommended that there was sufficient evidence of a treatment effect that warranted the termination of the study.

I think that the top line results will be good.